GlobeNewsWire
23 Jul 2026, 14:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Jyong Biotech's BPH drug candidate, Botreso®, has advanced to U.S. FDA Phase III clinical trials. — Phase III is the final stage before regulatory approval; success here is the primary driver of biotech valuation.
+0.60The company is actively pursuing global licensing partnerships with international pharmaceutical firms to commercialize its botanical drug platform. — Strategic partnerships and licensing agreements provide non-dilutive capital and validation from larger industry players.
+0.40The global BPH treatment market is projected to grow from $13 billion in 2025 to approximately $22 billion by 2035. — A growing total addressable market (TAM) increases the potential financial upside for any successful new entrant.
+0.30Continue reading
6 related stories
Search tags
Existing BPH treatments have high five-year discontinuation rates of 60% to 90% due to severe side effects. — Significant unmet medical needs create a market gap that Botreso® aims to fill, increasing the probability of market adoption.
+0.20Which stocks this story touches
The company is highlighting a multi-billion dollar market opportunity for its drug candidate and its progress in Phase III clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
5h ago
